Mediwound Ltd Ord Sh (MDWD) 7.33 $MDWD MediWound Reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mediwound Ltd Ord Sh (MDWD) 7.33 $MDWD

MediWound Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 5:45AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and six months ended June 30, 2016.
MDWD: 7.33 (-0.06)

Bear of the Day: Valeant Pharma (VRX)
Brian Hamilton - Zacks Investment Research - Thu Jul 14, 6:01AM CDT
Bear of the Day: Valeant Pharma (VRX)
ZTS: 50.47 (unch), VRX: 21.46 (-0.84), MDWD: 7.33 (-0.06)

MediWound's NexoBrid(R) Receives Reimbursement in Italy
GlobeNewswire - Tue Jun 07, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for NexoBrid for the removal of eschar in adults with deep partial and full-thickness thermal burns.
MDWD: 7.33 (-0.06)

MediWound to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at Jefferies 2016 Healthcare Conference taking place from June 7-10, 2016 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will deliver the Company's presentation on Wednesday, June 8th at 10:30 a.m. Eastern time.
MDWD: 7.33 (-0.06)

Data Published in Bone & Joint Research Supports MediWound's Bromelain-Based Enzyme for the Release of Dupuytren's Contracture
GlobeNewswire - Tue May 31, 6:30AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that a comprehensive review of injectable bromelain solution (IBS, or MWPC003) for the treatment of Dupuytren's contracture (DC) was published in the May 2016 edition of the peer-reviewed journal Bone & Joint Research. The online version of the review article, "A new bromelain-based enzyme for the release of Dupuytren's contracture," can be accessed here.
MDWD: 7.33 (-0.06)

MediWound's NexoBrid(R) Highlighted in "Best Oral Presentation" at the British Burn Association 49th Annual Conference and Scientific Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBridin the direct assessment of burn severity was selected as "Best Oral Presentation" at the British Burn Association's (BBA) 49 Annual Conference and Scientific Meeting. The BBA conference was held in Newcastle, England May 11-13, 2016, and the presentation, titled "Burn Depth Assessment: Laser Doppler Imaging (LDI) vs. Enzymatic Debridement," was delivered by Dr. Hendrik Hoeksema, Department of Plastic Surgery, University Ziekenhuis Hospital, Gent Belgium.
MDWD: 7.33 (-0.06)

MediWound's NexoBrid(R) to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting
GlobeNewswire - Mon May 02, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that 11 presentations highlighting the positive results achieved by clinicians using NexoBrid as an effective enzymatic debridement for severe burns will be presented during the American Burn Association (ABA) 48 Annual Meeting, taking place May 3-6, 2016 at Caesars Palace in Las Vegas.
MDWD: 7.33 (-0.06)

MediWound's NexoBrid to be Available in Japan through Kaken Pharmaceuticals Co., Ltd.
GlobeNewswire - Tue Apr 26, 6:02AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces the signing of an agreement granting Kaken Pharmaceuticals Co., Ltd. (KAKEN) (Tokyo Stock Exchange:4521) exclusive rights to develop and distribute NexoBrid in Japan for the treatment of severe burns.
MDWD: 7.33 (-0.06)

MediWound Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 21, 6:01AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three months ended March 31, 2016.
MDWD: 7.33 (-0.06)

MediWound to Host First Quarter 2016 Financial Results Conference Call on April 21, 2016 at 8:30 a.m. Eastern Time
GlobeNewswire - Thu Apr 14, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three months ended March 31, 2016, at 7:00 a.m. Eastern time on April 21, 2016.
MDWD: 7.33 (-0.06)

Top-Line Results from Phase 2 Study with MediWound's EscharEx to Treat Chronic Wounds Will be Presented at the Symposium on Advanced Wound Care Spring 2016
GlobeNewswire - Fri Apr 08, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that top-line data from a multicenter Phase 2 clinical study of the Company's EscharEx to treat chronic wounds will be presented in the Late-Breaking Session at the Spring Symposium on Advanced Wound Care (SAWC) 2016 taking place April 13-17, 2016 in Atlanta.
MDWD: 7.33 (-0.06)

MediWound to Present at Needham & Company's 15th Annual Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at Needham & Company's 15th Annual Healthcare Conference taking place from April 12-13, 2016 in New York City. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Tuesday, April 12th at 3:00 p.m. Eastern time.
MDWD: 7.33 (-0.06)

MediWound to Present at the 36th Annual Cowen Health Care Conference
GlobeNewswire - Mon Mar 07, 6:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 36 Annual Cowen Healthcare Conference taking place from March 7-9 at the Boston Marriot Copley Place in Boston. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Wednesday, March 9 at 9:20 a.m. Eastern time, with a breakout to follow at 10:00 a.m. Eastern time.
MDWD: 7.33 (-0.06)

MediWound's EscharEx(R) Meets Primary Endpoint in Second Phase 2 Clinical Trial for the Debridement of Chronic and Hard-to-Heal Wounds
GlobeNewswire - Tue Feb 02, 3:54PM CST
Data demonstrate strong results in diabetic foot ulcers and venous leg ulcers
MDWD: 7.33 (-0.06)

MediWound Reports 2015 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Mon Jan 25, 6:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and 12 months ended December 31, 2015.
MDWD: 7.33 (-0.06)

MediWound to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on January 25, 2016 at 8:30 a.m. Eastern Time
GlobeNewswire - Tue Jan 19, 7:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and twelve months ended December 31, 2015, at 7:00 a.m. Eastern time on January 25, 2016.
MDWD: 7.33 (-0.06)

MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters
GlobeNewswire - Mon Jan 11, 7:30AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that two presentations highlighting NexoBrid's potential role in managing Mass Casualty Incidence will be presented at the 4th International Conference on Preparedness and Response of Healthcare Systems to Emergencies and Disasters (IPRED IV), being held January 10 - 13, 2016 in Tel Aviv.
MDWD: 7.33 (-0.06)

Diabetic Foot Ulcers - Pipeline Review 2015
M2 - Wed Jan 06, 4:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/n92r2c/diabetic_foot) has announced the addition of the "Diabetic Foot Ulcers - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Adocia - Aprogen, Inc. - Bayer AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - CoDa Therapeutics, Inc. - CytoTools AG - Dipexium Pharmaceuticals LLC - EyeGene, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Human Stem Cells Institute - Innovaxis - Izun Pharmaceuticals Corporation - Karyopharm Therapeutics, Inc. - Lytix Biopharma AS - MediaPharma s.r.l. - MediWound Ltd. - NovaLead Pharma Pvt. Ltd. - Oneness Biotech Co., Ltd. - Osiris Therapeutics, Inc. - Plurogen Therapeutics, Inc. - Sanofi - Stratatech Corporation - TechnoPhage SA - TGV-Laboratories - Theravasc, Inc. - Tissue Med Biosciences - USV Limited For more information visit http://www.researchandmarkets.com/research/n9...betic_foot
DPRX: 10.52 (+0.08), OSIR: 5.02 (+0.02), MDWD: 7.33 (-0.06), GSK: 45.20 (+0.13), KPTI: 7.50 (+0.12), CELGZ: 1.13 (-0.03)

MediWound Ltd. Industry - Product Pipeline Review 2015 | Acute Market Reports
M2 - Tue Dec 22, 3:55AM CST
Acute Market Reports's, 'MediWound Ltd. - Product Pipeline Review - 2015', provides an overview of the MediWound Ltd.'s pharmaceutical research and development focus.
MDWD: 7.33 (-0.06)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 137

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 21

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 319

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 114

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 191

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Ryan Specialty Group's Strategic Push with Innovisk Acquisition

Updated Category News Views 151

Ryan Specialty Group's Acquisition Strategy Ryan Specialty Group (NYSE: RYAN), a prominent player in the specialty insurance sector, is on the brink of finalizing its acquisition of Innovisk Capital Partners. This move is primarily aimed at bolstering their underwriting capacity and expanding their overall market presence. The anticipated completion of the transaction is...

Continue Reading
Stifel Adjusts Align Technology Target Amid Restructuring Plans

Updated Category News Views 216

Stifel Adjusts Align Technology Target Price Recently, Stifel revised its outlook on Align Technology (NASDAQ: ALGN), lowering the price target from $285 to $275 while maintaining a Buy rating on the stock. This adjustment reflects the company's third-quarter financial performance, which met the expectations outlined in the analyst's prior survey. Performance Overview The...

Continue Reading
Golf Scramble Fundraiser to Empower Chicago's Youth Programs

Updated Category News Views 161

Golf Scramble Fundraiser to Empower Youth Nonprofit organization buildOn is excited to announce its inaugural Drive for Students Golf Scramble, a unique fundraiser focused on uniting students through service and education. This event is dedicated primarily to empowering young individuals and providing them the necessary tools to make a lasting impact in their communities....

Continue Reading
Key Highlights from Last Year's Most Notable Releases

Updated Category News Views 255

Overview of Press Releases That Made an Impact The past year was filled with significant announcements and updates that captured audience interest across various sectors. From recalls to growth strategies, the stories represented a multitude of companies and their evolving narratives. Top Press Releases of the Year Some highlights from the most widely read releases over...

Continue Reading
Thomas 'Biz Doc' Ellsworth Joins the Private Economic Council

Updated Category News Views 173

Thomas 'Biz Doc' Ellsworth Joins the Private Economic Council The Private Economic Council (PEC), a coalition of prominent economists, entrepreneurs, and policy makers, has welcomed Thomas Ellsworth to its influential roster. This news highlights Ellsworth's perceived value amidst a team dedicated to fostering economic growth. Experience and Background Ellsworth, known as...

Continue Reading